Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -90.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -90.42% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -90.42% | |||
| SG&A Expenses | 11.16% | 7.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.18% | -74.82% | |||
| Operating Income | -13.77% | 72.97% | |||
| Income Before Tax | -6.67% | 74.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.67% | 74.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.67% | 74.80% | |||
| EBIT | -13.77% | 72.97% | |||
| EBITDA | -13.80% | 73.03% | |||
| EPS Basic | -6.25% | 82.54% | |||
| Normalized Basic EPS | -13.82% | 82.16% | |||
| EPS Diluted | -6.25% | 82.54% | |||
| Normalized Diluted EPS | -13.82% | 82.16% | |||
| Average Basic Shares Outstanding | 0.40% | 44.35% | |||
| Average Diluted Shares Outstanding | 0.40% | 44.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||